UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone

NCT03139747 · clinicaltrials.gov ↗

PHASE2

Phase

SUSPENDED

Status

5

Enrollment

OTHER

Sponsor class

Stopped lack of accrual reevaluating feasibility

Conditions

Thyroid Cancer

Interventions

DRUG: Lenvatinib
DRUG: Everolimus

Sponsor

Thomas Jefferson University